Study of HER2 and P53 expression in meningioma and their relationship with histologic grade and reccurence

Meningiomas account for about 15–30% of all primary intracranial tumors. According to the 2007 WHO classification, meningiomas are divided into three grades (I, II and III). Recurrence is an issue following surgical treatment of meningioma, especially in grades II and III. HER2 (also known as erbB-2) is a 185-kD transmembrane glycoprotein with tyrosine kinase activity. HER2 is expressed in some human malignancies and can be a potential target for therapeutic intervention with selective inhibitors.
P53 is a totumor suppressor gene , which bond to DNA and stop cancer formation.
There are only a few studies on the relationship between meningioma and HER2 and P53 expression, and the results are different as well. The aim of this study was to determine this relationship.
Material and A total of fifty-seven paraffin blocks of meningioma were selected randomly, and immunohistochemical staining was then performed for each specimen.
Overall eight of the 57 meningiomas were HER2-positive and 6 of them were P53-positive. HER2 expression was observed in 4 (30%) of the 13 grade II/III or recurrent grade I , and 4 (9%) of the 44 grade I meningiomas without recurrenc.P53 expression was observed in 4 (30%) of the 13 grade II/III or reccurent grade I , and 2 (4.5%) of the 44 grade I meningiomas without reccrence. Consequently HER2 expression was detected in 14% of meningiomas and P53 expression was detected in 10.5% of them.
High grade meningioma and recurrent meningioma show more HER2 and P53 expression but significant difference was not seen between grade I without recurrence meningiomas and grade II/III meningioma or reccurent grade I meningiomas, from the point of view of HER2 and P53 expression. There is a signigicant relationship between p53 and her2 expression (P-Value=0.002). Study of HER2 and P53 expression may be useful for more accurate grading of meningioma.